Literature DB >> 21623645

Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential.

Carmen Noelker1, Harald Hampel, Richard Dodel.   

Abstract

Biomarker research is a rapidly advancing field in medicine. Recent advances in genomic, genetic, epigenetic, neuroscientific, proteomic, and metabolomic knowledge and technologies have opened the way to thriving research. In the most general sense, a biomarker refers to any useful characteristic that can be measured and used as an indicator of a normal biologic process, a pathogenic process, or a pharmacologic response to a therapeutic agent. Despite the extensive resources concentrated on this area, there are very few biomarkers currently available that qualify and are satisfactorily validated for mental disorders, and there is still a major lack of biomarkers for typifying neurodegenerative disorders such as Alzheimer's disease and Parkinson's disease. This article provides an overview of this field of research and focuses on recent advances in biomarker research in Alzheimer's disease and Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21623645     DOI: 10.1007/BF03256398

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN: 1177-1062            Impact factor:   4.074


  262 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

2.  Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease.

Authors:  F Blandini; R Fancellu; E Martignoni; A Mangiagalli; C Pacchetti; A Samuele; G Nappi
Journal:  Clin Chem       Date:  2001-06       Impact factor: 8.327

Review 3.  Apolipoprotein E polymorphisms and concentration in chronic diseases and drug responses.

Authors:  G Siest; P Bertrand; B Herbeth; M Vincent-Viry; F Schiele; C Sass; S Visvikis
Journal:  Clin Chem Lab Med       Date:  2000-09       Impact factor: 3.694

Review 4.  Inflammation and therapeutic vaccination in CNS diseases.

Authors:  Howard L Weiner; Dennis J Selkoe
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

Review 5.  Metabolomics in the study of aging and caloric restriction.

Authors:  Bruce S Kristal; Yevgeniya I Shurubor; Rima Kaddurah-Daouk; Wayne R Matson
Journal:  Methods Mol Biol       Date:  2007

Review 6.  Biomarkers of Alzheimer disease in plasma.

Authors:  Michael C Irizarry
Journal:  NeuroRx       Date:  2004-04

7.  Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

Authors:  D Blum-Degen; T Müller; W Kuhn; M Gerlach; H Przuntek; P Riederer
Journal:  Neurosci Lett       Date:  1995-12-29       Impact factor: 3.046

8.  alpha-Synuclein shares physical and functional homology with 14-3-3 proteins.

Authors:  N Ostrerova; L Petrucelli; M Farrer; N Mehta; P Choi; J Hardy; B Wolozin
Journal:  J Neurosci       Date:  1999-07-15       Impact factor: 6.167

9.  Activated human microglia produce the excitotoxin quinolinic acid.

Authors:  M G Espey; O N Chernyshev; J F Reinhard; M A Namboodiri; C A Colton
Journal:  Neuroreport       Date:  1997-01-20       Impact factor: 1.837

10.  Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma.

Authors:  Omar M A El-Agnaf; Sultan A Salem; Katerina E Paleologou; Leanne J Cooper; Nigel J Fullwood; Mark J Gibson; Martin D Curran; Jennifer A Court; David M A Mann; Shu-ichi Ikeda; Mark R Cookson; John Hardy; David Allsop
Journal:  FASEB J       Date:  2003-08-15       Impact factor: 5.191

View more
  8 in total

1.  Potential survival markers in cancer patients undergoing chemotherapy.

Authors:  Krzysztof Roszkowski; Jan Filipiak; Magdalena Wisniewska; Anna Mucha-Malecka; Pawel Basta
Journal:  Clin Exp Med       Date:  2014-09-28       Impact factor: 3.984

Review 2.  Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.

Authors:  Kaj Blennow; Harald Hampel; Henrik Zetterberg
Journal:  Neuropsychopharmacology       Date:  2013-06-25       Impact factor: 7.853

3.  DNA-Based Smart Reagent for Detecting Alzheimer's Associated MicroRNAs.

Authors:  Arun Richard Chandrasekaran; Ken Halvorsen
Journal:  ACS Sens       Date:  2021-09-07       Impact factor: 9.618

4.  Inflammatory proteins in plasma are associated with severity of Alzheimer's disease.

Authors:  Rufina Leung; Petroula Proitsi; Andrew Simmons; Katie Lunnon; Andreas Güntert; Deborah Kronenberg; Megan Pritchard; Magda Tsolaki; Patrizia Mecocci; Iwona Kloszewska; Bruno Vellas; Hilkka Soininen; Lars-Olaf Wahlund; Simon Lovestone
Journal:  PLoS One       Date:  2013-06-10       Impact factor: 3.240

5.  Circulating miRNA biomarkers for Alzheimer's disease.

Authors:  Pavan Kumar; Zoltan Dezso; Crystal MacKenzie; Judy Oestreicher; Sergei Agoulnik; Michael Byrne; Francois Bernier; Mamoru Yanagimachi; Ken Aoshima; Yoshiya Oda
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

Review 6.  Current status of biomarker research in neurology.

Authors:  Jiri Polivka; Jiri Polivka; Kristyna Krakorova; Marek Peterka; Ondrej Topolcan
Journal:  EPMA J       Date:  2016-07-04       Impact factor: 6.543

7.  A biosensor-based framework to measure latent proteostasis capacity.

Authors:  Rebecca J Wood; Angelique R Ormsby; Mona Radwan; Dezerae Cox; Abhishek Sharma; Tobias Vöpel; Simon Ebbinghaus; Mikael Oliveberg; Gavin E Reid; Alex Dickson; Danny M Hatters
Journal:  Nat Commun       Date:  2018-01-18       Impact factor: 14.919

8.  Evaluation of cerebrospinal fluid proteins as potential biomarkers for early stage Parkinson's disease diagnosis.

Authors:  Marcia Cristina T Dos Santos; Dieter Scheller; Claudia Schulte; Irene R Mesa; Peter Colman; Sarah R Bujac; Rosie Bell; Caroline Berteau; Luis Tosar Perez; Ingolf Lachmann; Daniela Berg; Walter Maetzler; Andre Nogueira da Costa
Journal:  PLoS One       Date:  2018-11-01       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.